STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
STAT [Unofficial]
June 1, 2026
The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.
Discussion in the ATmosphere